AI English summary of an SEC filing — figures as filed
McKesson MCKMcKesson said it will report financial results across four reportable segments—North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—commencing in Q2 of fiscal 2026, with its Norwegian operations included in Other.
Key points
AI summaryMcKesson said it will report financial results across four reportable segments—North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—commencing in Q2 of fiscal 2026, with its Norwegian operations included in Other.
The company said the segment changes did not impact its previously issued consolidated financial statements or historical earnings per diluted share. It explained the changes reflect how its Chief Executive Officer, as the chief operating decision maker, allocates resources and assesses performance.
McKesson said it announced its intention to separate the Medical-Surgical Solutions segment into an independent company in May 2025. The company also said it entered into a definitive agreement to sell its Norwegian operations on August 4, 2025, with the transaction subject to customary closing conditions, including receipt of required regulatory approvals.
McKesson disclosed that for the fiscal year ended March 31, 2025, North American Pharmaceutical segment revenues were $304,507 million, GAAP operating profit was $2,945 million, and adjusted operating profit (Non-GAAP) was $3,145 million. Total revenues were $359,051 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
4 Reportable Segments Beginning Q2 of Fiscal 2026
McKesson said it will report financial results across four reportable segments—North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—commencing in Q2 of fiscal 2026, with its Norwegian operations included in Other.
Source · Based on the filing body and exhibits
Previously Issued Consolidated Financial Statements and Earnings Per Diluted Share Unchanged
The company said the segment changes did not impact its previously issued consolidated financial statements or historical earnings per diluted share. It explained the changes reflect how its Chief Executive Officer, as the chief operating decision maker, allocates resources and assesses performance.
Source · Based on the filing body and exhibits
Medical-Surgical Separation Intention and Norwegian Operations Sale Agreement
McKesson said it announced its intention to separate the Medical-Surgical Solutions segment into an independent company in May 2025. The company also said it entered into a definitive agreement to sell its Norwegian operations on August 4, 2025, with the transaction subject to customary closing conditions, including receipt of required regulatory approvals.
Source · Based on the filing body and exhibits
Annual Revenues and Operating Profit by New Reportable Segment
McKesson disclosed that for the fiscal year ended March 31, 2025, North American Pharmaceutical segment revenues were $304,507 million, GAAP operating profit was $2,945 million, and adjusted operating profit (Non-GAAP) was $3,145 million. Total revenues were $359,051 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…